Influence of hepatic steatosis on the outcomes of patients with chronic hepatitis B treated with entecavir and tenofovir
1
조회
0
다운로드
7
인용
0
참고문헌
키워드
초록
Background/Aims: The influence of hepatic steatosis (HS) on chronic hepatitis B (CHB) is unclear. We evaluated the influence of the degree of HS, assessed using the controlled attenuation parameter (CAP) of transient elastography (TE), on treatment outcomes in CHB patients initiated on antiviral therapy. Methods: A total of 334 patients who were initiated on entecavir or tenofovir between 2007 and 2016 with available TE results were recruited. Results: Of the total study population, 146 (43.7%) patients had HS (CAP >238 dB/m). Three-hundred-three patients (90.7%) achieved complete virological response (CVR) (hepatitis B virus DNA <12 IU/L), and 25 patients (7.5%) developed hepatocellular carcinoma (HCC). Among hepatitis B e antigen (HBeAg)-positive patients (n=172, 51.5%), 37 (21.5%) experienced HBeAg loss. On univariate analysis, CAP value was not associated with the probability of HCC development (P =0.380). However, lower CAP value was independently associated with higher probability of HBeAg loss among HBeAg-positive patients (hazard ratio [HR]=0.991, P =0.026) and with CVR achievement in the entire study population (HR=0.996, P=0.004). The cumulative incidence of HBeAg loss among HBeAg-positive patients was significantly higher in patients without HS than in those with HS (log-rank, P =0.022). Conclusions: CAP values were not correlated with HCC development in patients initiated on entecavir and tenofovir. However, CAP values were negatively correlated with the probability of HBeAg loss among HBeAg-positive patients and with CVR achievement.
Abstract
Background/Aims: The influence of hepatic steatosis (HS) on chronic hepatitis B (CHB) is unclear. We evaluated the influence of the degree of HS, assessed using the controlled attenuation parameter (CAP) of transient elastography (TE), on treatment outcomes in CHB patients initiated on antiviral therapy. Methods: A total of 334 patients who were initiated on entecavir or tenofovir between 2007 and 2016 with available TE results were recruited. Results: Of the total study population, 146 (43.7%) patients had HS (CAP >238 dB/m). Three-hundred-three patients (90.7%) achieved complete virological response (CVR) (hepatitis B virus DNA <12 IU/L), and 25 patients (7.5%) developed hepatocellular carcinoma (HCC). Among hepatitis B e antigen (HBeAg)-positive patients (n=172, 51.5%), 37 (21.5%) experienced HBeAg loss. On univariate analysis, CAP value was not associated with the probability of HCC development (P =0.380). However, lower CAP value was independently associated with higher probability of HBeAg loss among HBeAg-positive patients (hazard ratio [HR]=0.991, P =0.026) and with CVR achievement in the entire study population (HR=0.996, P=0.004). The cumulative incidence of HBeAg loss among HBeAg-positive patients was significantly higher in patients without HS than in those with HS (log-rank, P =0.022). Conclusions: CAP values were not correlated with HCC development in patients initiated on entecavir and tenofovir. However, CAP values were negatively correlated with the probability of HBeAg loss among HBeAg-positive patients and with CVR achievement.
참고문헌 (30)
- World Health Organization, "Hepatitis B vaccines : WHO position paper, July 2017-Recommendations", Vaccine, 37, pp.223~225 (2019)
- Ikeda K, "Disease progression and hepatocellular carcinogenesis in patients with chronic viral hepatitis : a prospective observation of 2215 patients", J Hepatol, 28, pp.930~938 (1998)
- Sookoian S, "Genetic predisposition in nonalcoholic fatty liver disease", Clin Mol Hepatol, 23, pp.1~12 (2017)
- European Association for the Study of the Liver, "EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection", J Hepatol, 67, pp.370~398 (2017)
- Snow-Lampart A, "No resistance to tenofovir disoproxil fumarate detected after up to 144 weeks of therapy in patients monoinfected with chronic hepatitis B virus", Hepatology, 53, pp.763~773 (2011)
- Fan JG, "New trends on obesity and NAFLD in Asia", J Hepatol, 67, pp.862~873 (2017)
- Wang CC, "Association of chronic hepatitis B virus infection with insulin resistance and hepatic steatosis", J Gastroenterol Hepatol, 23, pp.779~782 (2008)
- Shi JP, "Prevalence and risk factors of hepatic steatosis and its impact on liver injury in Chinese patients with chronic hepatitis B infection", J Gastroenterol Hepatol, 23, pp.1419~1425 (2008)
- Wong VW, "Interaction of adipokines and hepatitis B virus on histological liver injury in the Chinese", Am J Gastroenterol, 105, pp.132~138 (2010)
- Zhu Y, "The effect of hepatosteatosis on response to antiviral treatment in patients with chronic hepatitis B : a metaanalysis", Gastroenterol Res Pract, 2017, pp.1096406~ (2017)
- Machado MV, "Hepatic steatosis in hepatitis B virus infected patients : meta-analysis of risk factors and comparison with hepatitis C infected patients", J Gastroenterol Hepatol, 26, pp.1361~1367 (2011)
- Seto WK, "Association between hepatic steatosis, measured by controlled attenuation parameter, and fibrosis burden in chronic hepatitis B", Clin Gastroenterol Hepatol, 16, pp.575~583 (2018)[DOI]
- Wong GL, "Metabolic syndrome increases the risk of liver cirrhosis in chronic hepatitis B", Gut, 58, pp.111~117 (2009)
- 한광협, "The Relationship between Type 2 Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease Measured by Controlled Attenuation Parameter", Yonsei Medical Journal, 57(4), pp.885~892 (2016), 연세대학교의과대학[DOI]
- Kim BK, "Risk assessment of clinical outcomes in Asian patients with chronic hepatitis B using enhanced liver fibrosis test", Hepatology, 60, pp.1911~1919 (2014)
- Seo YS, "Risk assessment of hepatocellular carcinoma using transient elastography vs. liver biopsy in chronic hepatitis B patients receiving antiviral therapy", Medicine (Baltimore), 95, pp.e2985~ (2016)
- Lee DH, "Imaging evaluation of non-alcoholic fatty liver disease : focused on quantification", Clin Mol Hepatol, 23, pp.290~301 (2017)
- Jem Ma Ahn, "Acute hepatitis A; Cytotoxic T lymphocyte-associated antigen 4; Programmed death 1", Gut and Liver, 10(2), pp.295~302 (2016), 거트앤리버 소화기연관학회협의회
- Ceylan B, "Impact of fatty liver on hepatitis B virus replication and virologic response to tenofovir and entecavir", Turk J Gastroenterol, 27, pp.42~46 (2016)
- Lok AS, "Antiviral drug-resistant HBV : standardization of nomenclature and assays and recommendations for management", Hepatology, 46, pp.254~265 (2007)
- Kim MN, "Increased risk of hepatocellular carcinoma in chronic hepatitis B patients with transient elastography-defined subclinical cirrhosis", Hepatology, 61, pp.1851~1859 (2015)
- 김자경, "Usefulness of the Controlled Attenuation Parameter for Detecting Liver Steatosis in Health Checkup Examinees", Gut and Liver, 9(3), pp.405~410 (2015), 거트앤리버 소화기연관학회협의회
- Bruix J, "Management of hepatocellular carcinoma: an update", Hepatology, 53, pp.1020~1022 (2011)
- Jung KS, "Risk assessment of hepatitis B virus-related hepatocellular carcinoma development using liver stiffness measurement(FibroScan)", Hepatology, 53, pp.885~894 (2011)
- Marcellin P, "Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B : a 5-year open-label follow-up study", Lancet, 381, pp.468~475 (2013)
- Zhu LY, "The effects of the insulin resistance index on the virologic response to entecavir in patients with HBeAg-positive chronic hepatitis B and nonalcoholic fatty liver disease", Drug Des Devel Ther, 10, pp.2739~2744 (2016)
- Seto WK, "Nonalcoholic fatty liver disease in Asia : emerging perspectives", J Gastroenterol, 52, pp.164~174 (2017)
- Wong VW, "Hepatitis B virus infection and fatty liver in the general population", J Hepatol, 56, pp.533~540 (2012)
- Lau E, "Gut microbiota : association with NAFLD and metabolic disturbances", Biomed Res Int, 2015, pp.979515~ (2015)
- Takahashi Y, "Histopathology of nonalcoholic fatty liver disease", nonalcoholic steatohepatitis, 2014, pp.20, 15539~15548